Protocol Ledger

NCT04138277 · Phase III · COMPLETED

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Interventional Phase III clinical trial protocol NCT04138277 sponsored by Amicus Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-18 Enrollment: 119 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04138277
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)119 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04138277
Protocol FieldVerified Registry Value
NCT IdentifierNCT04138277
Consolidated Lead SponsorAmicus Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment119 participants (ACTUAL)
Registered Start Date2019-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI